Company intelligence / Profile preview
TransPharma Medical Ltd.
- Ownership
- Private
- Development stage
- Phase 2
Overview
TransPharma Medical developed a proprietary active transdermal drug delivery platform and advanced several programs into early clinical development. The ViaDerm/GLP‑1 agonist completed a Phase I trial by September 2010. An insulin patch was also in development for diabetes. There are no recent published results or late-stage data available.
- Therapeutic areas
- Endocrinology
- Modalities
- transdermal drug delivery (including peptides, proteins, small molecules)radio-frequency microchannel technology for transdermal delivery
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on TransPharma Medical Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TransPharma Medical Ltd..